[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@FierceBiotech FierceBiotech
FierceBiotech posts on X about has been, blockbuster, $mrk, london the most. They currently have XXXXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX +2,684%
- X Month XXXXXX -XX%
- X Months XXXXXXX +15%
- X Year XXXXXXX -X%
Mentions: XX #
- X Week XX +21%
- X Month XX +8.10%
- X Months XXX -XX%
- X Year XXX +21%
Followers: XXXXXXX #
- X Week XXXXXXX +0.05%
- X Month XXXXXXX +0.13%
- X Months XXXXXXX +0.56%
- X Year XXXXXXX -XXXX%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence stocks travel destinations technology brands
Social topic influence has been, blockbuster, $mrk, london, the project, $nvo, eli lilly, $lly, gilead sciences, $bmy #33
Top assets mentioned Merck & Co., Inc. (MRK) Novo-Nordisk (NVO) Eli Lilly and Company (LLY) Gilead Sciences, Inc. (GILD) Bristol-Myers Squibb Co (BMY) Denali Therapeutics Inc. Common Stock (DNLI)
Top Social Posts #
Top posts by engagements in the last XX hours
"Novo Nordisk hasstruck a deal to buy Akero Therapeutics for up to $XXX billion teeing up a showdown with Roche and others in a blockbuster liver disease market"
X Link @FierceBiotech 2025-10-09T14:52Z 101.7K followers, 1917 engagements
"Less than two years after breaking ground on a $XXX billion R&D center and future U.K. headquarters in London Merck & Co. is bailing on the project and discontinuing all research operations in Britain citing an unwelcoming business environment. $MRK"
X Link @FierceBiotech 2025-09-10T19:59Z 101.7K followers, 77.2K engagements
"After Omeros hit pause on developing its MASP-3 inhibitor zaltenibart Novo Nordisk is offering up to $XXX billion to scoop the rare disease drug. $NVO"
X Link @FierceBiotech 2025-10-15T14:34Z 101.7K followers, 1026 engagements
"Lilly shared oral GLP-1 data from two of the remaining three trials in its diabetes program racking up wins against placebo and AstraZenecas Farxiga. $LLY"
X Link @FierceBiotech 2025-10-15T15:01Z 101.7K followers, XXX engagements
"Bristol Myers Squibb hasagreed to pay $XXX billion to buy Orbital Therapeutics for a pipeline led by a preclinical CD19 autoimmune program"
X Link @FierceBiotech 2025-10-10T14:30Z 101.7K followers, 3658 engagements
"Ono Pharmaceuticals EP4 antagonist hit the primary progression-free survival endpoint in a phase X trial in patients with gastric cancer"
X Link @FierceBiotech 2025-10-09T14:52Z 101.7K followers, 3837 engagements
"Two ex-Moderna leaders have hit a milestone in their new endeavor closing a $XXX million inaugural fund for their biotech venture capital firm called Ascenta"
X Link @FierceBiotech 2025-10-09T19:49Z 101.7K followers, 2832 engagements
"Gilead Sciences and Arcus Biosciences anti-TIGIT antibody domvanalimab has been tied to median overall survival of close to XX months keeping alive one of the last remaining hopes for this once-hyped modality"
X Link @FierceBiotech 2025-10-13T18:30Z 101.7K followers, 3505 engagements
"Pushing deeper into in vivo cell therapies BMS hasagreed to pay $XXX billion to buy Orbital Therapeutics for a pipeline led by a preclinical CD19 autoimmune program. $BMY"
X Link @FierceBiotech 2025-10-10T15:17Z 101.7K followers, 2160 engagements
"The FDA has delayed an approval decision for Denali's enzyme replacement therapy designed to treat a rare genetic disorder called Hunter syndrome. The decision has been pushed back three months to April X. $DNLI"
X Link @FierceBiotech 2025-10-14T12:46Z 101.7K followers, 2150 engagements